Displaying 1 - 7 of 7
9 June 2020
In this presentation, WaterAid shared their response to COVID-19 in Asia and the Pacific, specifically in the eight countries they work in: Bangladesh, Cambodia, India, Myanmar, Nepal, Pakistan, Papua New Guinea, and Timor-Leste. Given the changing dynamics of the pandemic, WaterAid has taken a…
27 January 2020
This material introduces the climate change vulnerability of Myanmar and emphasizes the importance of the flood early warning system in managing disaster risk. It also gives an overview of the current flood warning-related systems in Mayanmar and discusses the government’s future plans.
1 May 2019
This presentation showcases Health Impact Assessments (HIAs) undertaken as part of pilot projects from key infrastructure sectors in the Greater Mekong Subregion (GMS), including urban development, transport, energy, water, and social development. Challenges, priorities, and key issues arising are…
1 May 2019
There are over 500 special economic zones (SEZs) across the Greater Mekong Subregion (GMS). This HIA framework was developed to identify, mitigate, and manage health risks and impacts in economic zones of the Greater Mekong Subregion and address transboundary issues associated with human migration…
1 May 2019
The Thilawa Special Economic Zone is the first operational SEZ in Myanmar and one of the largest industrial development. Thilawa SEZ recognized the need for proper hazardous material management in addition to waste management to avoid accidents such as chemical accidents and explosions. It has…
1 May 2019
Years of experience on Health Impact Assessment (HIA) and safeguard processes provided the momentum to strengthen HIA practice within ADB procedures and its developing member countries (DMCs). This presentation outlines how ADB has strengthened HIA over the last 3 years. This was done through…
25 January 2018
There is no room for malaria in Myanmar. Health expert Valerio Reggi shares Myanmar's moves to eliminate the disease.
ADB is helping to strengthen Myanmar's regulatory capacity; ensure effective assessments of medicines; and reduce the risk of substandard and falsified medicines, particularly anti…